Pharvaris N.V. Ordinary Shares (PHVS)
Stock · NASDAQ · Health Care
$35.32as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
Support level
$25.68
Industry
Biotechnology: Pharmaceutical Preparations
About PHVS
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema du…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 148
- Website
- pharvaris.com
Fundamentals
- 1-day range
- $33.54$36.18
- Market cap
- $2.25B
- P/E (trailing)
- —
- P/E (forward)
- -11.37
- EPS (trailing)
- $-3.00
- Dividend yield
- —
- Beta
- -2.33
- Avg. volume
- 456.0K
52-week range
$20.65$36.93
Forecasts
14 analyst ratings
Buy 93%
Hold 7%
Sell 0%
1-year price forecast
High
$75.28
+113.1%
Median
$46.74
+32.3%
Low
$35.55
+0.6%
Pharvaris N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- PHVSPharvaris N.V. Ordinary Shares$35.32▼ 4.54%Market cap $2.25BP/E —$20.65$36.93
- KLRAKailera Therapeutics Inc. Common Stock$16.26▼ 12.25%Market cap $2.24BP/E —$16.19$28.23
- VERAVera Therapeutics Inc. Class A Common Stock$34.19▼ 1.18%Market cap $2.31BP/E —$21.2$56.05
- NUVBNuvation Bio Inc. Class A Common Stock$6.67▼ 4.65%Market cap $2.14BP/E —$2.87$9.75
- PGENPrecigen Inc. Common Stock$6.94▼ 3.55%Market cap $2.36BP/E —$2.99$7.72
- MLYSMineralys Therapeutics Inc. Common Stock$25.59▼ 1.61%Market cap $2.13BP/E —$14.94$47.65
- NKTRNektar Therapeutics Common Stock$72.57▼ 2.66%Market cap $2.38BP/E —$27.87$109
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PHVS Pharvaris N.V. Ordinary Shares | $2.25B | — | $35.32 | ▼ 4.54% | $20.65$36.93 |
| KLRA Kailera Therapeutics Inc. Common Stock | $2.24B | — | $16.26 | ▼ 12.25% | $16.19$28.23 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.31B | — | $34.19 | ▼ 1.18% | $21.2$56.05 |
| NUVB Nuvation Bio Inc. Class A Common Stock | $2.14B | — | $6.67 | ▼ 4.65% | $2.87$9.75 |
| PGEN Precigen Inc. Common Stock | $2.36B | — | $6.94 | ▼ 3.55% | $2.99$7.72 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.13B | — | $25.59 | ▼ 1.61% | $14.94$47.65 |
| NKTR Nektar Therapeutics Common Stock | $2.38B | — | $72.57 | ▼ 2.66% | $27.87$109 |
P/E shows — for peers not currently carrying a live signal of their own.
See the full, filterable feed with live charts on the MarketWall dashboard.